Telomerase Inhibitor Imetelstat in Patients with Essential Thrombocythemia | Zendy

Gabriela M. Baerlocher | Zendy; Elisabeth Oppliger Leibundgut | Zendy; Oliver G. Ottmann | Zendy; Gary Spitzer | Zendy; Olatoyosi Odenike | Zendy; Michael A. McDevitt | Zendy; Alexander Röth | Zendy; Michael Daskalakis | Zendy; Bart Burington | Zendy; Monic J. Stuart | Zendy; David S. Snyder | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Telomerase Inhibitor Imetelstat in Patients with Essential Thrombocythemia

Author(s) -

Gabriela M. Baerlocher,

Elisabeth Oppliger Leibundgut,

Oliver G. Ottmann,

Gary Spitzer,

Olatoyosi Odenike,

Michael A. McDevitt,

Alexander Röth,

Michael Daskalakis,

Bart Burington,

Monic J. Stuart,

David S. Snyder

Publication year - 2015

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1503479

Subject(s) - essential thrombocythemia , medicine , adverse effect , gastroenterology , neutropenia , platelet , surgery , chemotherapy

Imetelstat, a 13-mer oligonucleotide that is covalently modified with lipid extensions, competitively inhibits telomerase enzymatic activity. It has been shown to inhibit megakaryocytic proliferation in vitro in cells obtained from patients with essential thrombocythemia. In this phase 2 study, we investigated whether imetelstat could elicit hematologic and molecular responses in patients with essential thrombocythemia who had not had a response to or who had had unacceptable side effects from prior therapies.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research